Microdosed dried mushrooms associated with remission of refractory depression and anxiety in neuropsychiatric Lyme disease

Source note

Anonymised summary of a published case study (PMC9990519). Names and clinic-identifying details are removed.

Participant profile (non-identifying)

• Age / sex: 70-year-old male
• Context: serologically positive neuropsychiatric Lyme disease with severe depression, anxiety, and sleep disturbance; immunocompetent
• Prior care: relapse after antimicrobial regimen change; intolerance of further antimicrobials; benzodiazepines worsened depression; sertraline without benefit

Reported regimen

• Dried whole mushrooms microdosed orally at 100 mg three times weekly, increased to 125 mg after two weeks
• Described as sub-hallucinogenic / microdose range by the authors

Reported outcome

• Noticeable mood improvement within two days
• Consistent wellness within two weeks
• Continued regimen with depression and anxiety remaining in remission at two-year follow-up in the report

Limitations

• Single case; expectancy and concurrent illness course cannot be ruled out
• Botanical product without pharmaceutical assay
• Lyme / autoimmune comorbidity limits generalisation to primary MDD or GAD

Why included

Illustrates a published microdosing anecdote for anxiety–depression symptoms outside classic TRD trial populations, while remaining low-evidence relative to RCTs.